The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)

被引：0

作者：

Deng, Y. ^{[1
]}

Liu, H. ^{[2
]}

Xie, L. ^{[3
]}

Zhang, J. ^{[1
]}

Hu, H. ^{[1
]}

Liu, Z. ^{[4
]}

Wang, W. ^{[5
]}

Yu, X. ^{[6
]}

Wang, Z. M. ^{[6
]}

Li, B. ^{[6
]}

Xia, Y. ^{[6
]}

机构：

[1] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Oncol, Guangzhou, Peoples R China

[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China

[3] Yunnan Canc Hosp, Dept Gastroenterol & Internal Oncol, Kunming, Yunnan, Peoples R China

[4] Hunan Canc Hosp, Affiliated Canc Hosp, Dept Gastroenterol & Urol, Xiangya Sch Med, Changsha, Peoples R China

[5] First Peoples Hosp Foshan, Dept Gastrointestinal Oncol, Foshan, Peoples R China

[6] Akeso Biopharma Inc, Dept Med, Zhongshan, Peoples R China

来源：

关键词：

D O I：

10.1016/j.annonc.2024.08.583

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

514MO

引用

页码：S435 / S435

页数：1